Do you alter definitive treatment recommendations for oropharynx p16+ cancers based on the new staging?

The new AJCC staging factors in HPV status and can drastically alter a patients overall stage group, hence dramatically change definitive treatment recommendations from CRT to RT alone compared to the old staging.

Answer from: Radiation Oncologist at Community Practice

As you know, the new 8th Edition of the AJCC staging manual redefined prognostic staging for p16/HPV-positive tumors. It is important to note that p16/HPV is therefore not a PROGNOSTIC marker but rather a DIAGNOSTIC biomarker of a different disease entity entirely. The 8th Edition system is based of...

Comments

Radiation Oncologist at University of Wisconsin School of Medicine and Public Health
I agree with this. Do not alter treatment based on...

Answer from: Radiation Oncologist at Academic Institution

We have not altered definitive treatment recommendations for p16+ oropharyngeal cancer since the introduction of the new AJCC staging.

Please select the option that best describes you:

Do you alter definitive treatment recommendations for oropharynx p16+ cancers based on the new staging?

Related Questions